Does central nervous system dysfunction underlie patellofemoral pain in young females? Examining brain functional connectivity in association with patient‐reported outcomes

2021 ◽  
Author(s):  
Jed A. Diekfuss ◽  
Dustin R. Grooms ◽  
Katharine S. Nissen ◽  
Robert C. Coghill ◽  
Scott Bonnette ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Functional Connectivity ◽  
Patient Reported Outcomes ◽  
Patellofemoral Pain ◽  
Young Females ◽  
Central Nervous System Dysfunction ◽  
Patient Reported ◽  
Brain Functional Connectivity

scholarly journals Severe Gastrooesophageal Reflux Disease Associated with Foetal Alcohol Syndrome

2012 ◽  
Vol 2012 ◽  
pp. 1-3
Author(s):  
N. K. Sujay ◽  
Matthew Jones ◽  
Emma Whittle ◽  
Helen Murphy ◽  
Marcus K. H. Auth
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Gastrointestinal Tract ◽  
Reflux Disease ◽  
Prenatal Alcohol Exposure ◽  
Case Reports ◽  
Alcohol Exposure ◽  
Central Nervous System Dysfunction ◽  
Foetal Alcohol Syndrome ◽  
Gastrooesophageal Reflux

Prenatal alcohol exposure may have adverse effects on the developing foetus resulting in significant growth restriction, characteristic craniofacial features, and central nervous system dysfunction. The toxic effects of alcohol on the developing brain are well recognised. However, little is known about the effects of alcohol on the developing gastrointestinal tract or their mechanism. There are few case reports showing an association between foetal alcohol syndrome and gastrointestinal neuropathy. We report a rare association between foetal alcohol syndrome and severe gastrooesophageal reflux disease in an infant who ultimately required fundoplication to optimise her growth and nutrition. The child had failed to respond to maximal medical treatment (domperidone and omeprazole), high calorie feeds, PEG feeding, or total parenteral nutrition. The effect of alcohol on the developing foetus is not limited to the central nervous system but also can have varied and devastating effects on the gastrointestinal tract.

INFLUENZA-ASSOCIATED CENTRAL NERVOUS SYSTEM DYSFUNCTION IN TAIWANESE CHILDREN

2009 ◽  
Vol 28 (7) ◽  
pp. 647-648 ◽  
Author(s):  
Yhu-Chering Huang ◽  
Wen-Chen Li ◽  
Kuo-Chien Tsao ◽  
Chung-Guei Huang ◽  
Cheng-Hsun Chiu ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Central Nervous System Dysfunction

EPID-24. TRANSCRIPT: A cenTRAl NERVOUS SYSTEM CANCER CLINICAL tRIals PostmorTem

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi91-vi91
Author(s):  
Yeonju Kim ◽  
Terri Armstrong ◽  
Mark Gilbert ◽  
Orieta Celiku
Keyword(s):  
Central Nervous System ◽  
Overall Survival ◽  
Clinical Trials ◽  
Nervous System ◽  
Brain Tumor ◽  
Objective Response ◽  
Survival Rates ◽  
Maximum Tolerated Dose ◽  
Secondary Outcome ◽  
Patient Reported

Abstract BACKGROUND Despite the growing number of neuro-oncology clinical trials, there have been limited advances in the treatment of malignant primary central nervous system tumors. We surveyed the landscape of past, ongoing, and planned trials to assess trends in their interventions, outcomes, and design considerations to guide future studies. METHODS Data on interventional trials on ClinicalTrials.gov were accessed programmatically using AACT and R. Neuro-oncology trials were isolated using primary malignant brain tumor classification terms. Instrument names from PROQOLID were used to identify clinical outcome assessment (COA) use. Linear regression was used to assess chronological trends; power analyses utilized CBTRUS survival rates among trials investigating overall survival. RESULTS We identified 3039 interventional brain tumor trials that started between 1966 and 2025. Trials were most frequently phase II (43%), completed (40%), non-blinded (92%), single-group assignment (65%), non-randomized (51%) studies targeting glioblastoma (45%). Planned outcomes were reported by 93% of trials; this included adverse event or toxicity (54%), overall/x-year survival (44%), progression free survival (43%), maximum tolerated dose (16%), and objective response rate (14%). Evaluating the anticipated and actual trial enrollment, we estimate that only 10% and 8% of trial arms, respectively, were sufficiently powered to assess overall survival endpoints. 21% of trials mentioned the use of a COA (first trial initiated in 1992), majority of which were patient-reported outcomes. Among these, 25% and 58% reported COA as a primary or secondary outcome, respectively. The rate of COA use increased linearly over time at 1.1%/year but remained less than 5 trials per year until 2003. Ongoing work is investigating treatment mechanisms of actions and evidence of preclinical efficacy among brain tumor studies. CONCLUSIONS Low randomization rates and underpowered trial design may impede interpretability of efficacy. Increasing trends in COA use suggests cumulative influence of advocacy efforts to holistically evaluate net clinical benefit of interventions.

Sign in / Sign up

Export Citation Format

Share Document